Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 6/20 | 0.44 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.44 |
| ▸ | TET3 | O43151 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | FBXL19 | Q6PCT2 | 3/20 | 0.40 |
| ▸ | CXXC5 | Q7LFL8 | 3/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.40 |
| ▸ | CXXC4 | Q9H2H0 | 3/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.40 |
| ▸ | TET1 | Q8NFU7 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 4/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237862 | 0.84 | — | — | |
| SCHEMBL12764449 | 0.84 | TET3 (0.47) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL167151 | 0.84 | TET3 (0.47) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL20547259 | 0.84 | TET3 (0.47) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL2941527 | 0.84 | TEAD1 (0.43) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL29728768 | 0.84 | TEAD1 (0.43) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL20780999 | 0.82 | TEAD1 (0.42) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL463245 | 0.82 | ALDH1A1 (0.48) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL12163604 | 0.82 | TEAD1 (0.42) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL12840752 | 0.82 | TEAD1 (0.45) | TEAD1TEAD3TET3KMT2AFBXL19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| CN-114989140-A | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114940673-A | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3922630-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Capella Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3119762-B9 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3119762-B1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210061816-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20180291012-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS INC (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180273511-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2018-09-27 | — | — | US | disclosed |
| US-10005765-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170174697-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2017053537-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| EP-3119784-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Capella Therapeutics, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119762-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Capella Therapeutics, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015143148-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015143161-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174697-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | TEAD1 1000/4885TEAD3 867/4885TET3 4527/4885 |
| US-20180273511-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | TEAD1 3152/4885TEAD3 3708/4885TET3 4572/4885 |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CCNI, CYP2C19, PHB1 | TEAD1 2215/4885TEAD3 1810/4885TET3 3160/4885 |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | TEAD1 826/4885TEAD3 784/4885TET3 4573/4885 |
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | TEAD1 921/4885TEAD3 811/4885TET3 4492/4885 |
| US-10005765-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | TEAD1 826/4885TEAD3 784/4885TET3 4573/4885 |
| US-20180291012-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | TEAD1 826/4885TEAD3 784/4885TET3 4573/4885 |
| US-20210061816-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | TEAD1 1000/4885TEAD3 867/4885TET3 4527/4885 |
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | TEAD1 1000/4885TEAD3 867/4885TET3 4527/4885 |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | TEAD1 3152/4885TEAD3 3708/4885TET3 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.